gene2lead logo

About us

At Gene2Lead, we incorporate AI-based computational pipelines to existing medicinal chemistry-based drug discovery programs.

We are developing an AI-integrated platform technology that unmasks difficult drug targets and generates therapeutics against them, revealing high-value and previously inaccessible biomolecule targets that can potentially be applied to a range of diseases.

Our platform offers drug discovery programs with comprehensive structural insights for identifying druggable binding sites protein protein-analyzing ligand binding modes and computationally generating rational drug design ideas in a robust scale-up and expedited fashion. We receive client projects at the level of a target gene of interest and work it through a semi-automated customized high throughput project pipeline to identify novelty lead drug molecules for experimental testing.

Program engagement

Gene2Lead

Leadership

Patrick Gunning

Co-Founder

Elvin de Araujo

Operations Advisor

Serap Beldar

Scientific and Marketing Consultant

Status

Intellectual Property

Fundraising

Sector

Subsector